胡海燕

聯系方式

辦公電話：020-39336530(O)

電子郵箱：lsshhy@mail.sysu.edu.cn

辦公地址：廣州市大學城外環東路132号 太阳集团1088vip214B室 郵編：510006

簡單介紹

胡海燕，女，教授，博士生導師。中國藥學會藥劑學專委會委員，中國抗癌協會納米腫瘤學專業委員會委員，中國民族醫藥學會布朗醫藥分會常務理事；Eur J Pharm Biopharm, Molecules和《藥學學報》雜志編委。研究方向主要包括：1)生物被膜靶向遞藥系統；2)毛發健康相關遞藥系統；3)消化道疾病智能遞藥系統。以第一作者或通訊作者在J Control Release、Acta Pharm Sin B，Carbohyd Polym等發表學術論文50餘篇，獲得10餘項中國專利授權。主持“十二五”“重大新藥創制”、國家自然科學基金面上項目（5項）、廣州市科技計劃重點項目、廣東省自然科學基金、中山大學交叉學科培育項目等課題。

教育經曆

2014/11-2015/11 英國諾丁漢大學，訪問學者

2008/05-2008/08 美國Huahai US Co., Ltd.，Senior Research Fellow

2003/09-2006/06 四川大學，獲得藥劑學博士學位；

1995/09-1998/06 華西醫科大學（現四川大學），獲得藥劑學碩士學位

1991/09-1995/06 華西醫科大學（現四川大學），獲得藥學學士學位

工作經曆

2017/1至今 太阳集团1088vip教授

2016/4-2017/4 滇西應用技術大學傣醫太阳集团1088vip副院長(挂職)

2010/1-2017/1 太阳集团1088vip副教授

1998/7-2010/1 太阳集团1088vip（系）助教、講師

教學情況

本科生課程 藥劑學實驗（課程負責人）、 藥劑學

研究生課程 藥劑學進展（課程負責人）、改良型新藥的開發與轉化（課程負責人）、崗位認知（課程負責人）

社會/學術任職

《藥學學報》編委

Eur J Pharm Biopharm編委

Molecules編委

中國藥學會藥劑學專委會委員

中國民族醫藥學會布朗醫藥分會常務理事

中國抗癌協會納米腫瘤學專業委員會委員

科研項目

[1]國家自然科學基金面上項目：脲酶響應型非抗生素抗生物被膜聯合免疫激活自組裝納米膠束的構建及清除幽門螺杆菌作用機制的研究（課題負責人，No.82273870，2023～2026年）

[2]國家自然科學基金面上項目：針對銅綠假單胞菌菌膜所緻頑固性肺部感染的全過程智能遞藥系統的構建及其阻斷細菌耐藥發生的機制研究（課題負責人，No. 81973264，2020～2023年）

[3] 國家自然科學基金面上項目：仿病毒親水富電表面介孔二氧化矽納米粒的構建及其克服胰島素口服吸收多重屏障的機制研究（課題負責人，No. 81773659，2018～2021年）

[4] 國家自然科學基金面上項目：靶向降解、清除幽門螺杆菌菌膜 (biofilm)的多功能脂質-聚合物雜化納米粒的制備、作用評價及相關機制研究（課題負責人，No. 81473154，2015～2018年）

[5] 國家自然科學基金面上項目：膽固醇代謝産物Triol作為内源性神經保護因子的發現及其作用機制研究”（課題負責人，No. 81173045，2012～2015年）

[6] “十二五”國家科技重大專項“重大新藥創制”：針對歐洲市場阿奇黴素制劑的研發與産業化（課題負責人，No. 2011ZX09202-101-06 ，2011～2014年）

[7] 廣州市科技計劃重點項目：清除幽門螺杆菌感染緩解胃黏膜損傷非抗生素制劑的研發與産業化（課題負責人，No. 2023B03J0022，2023～2026年）

[8] 廣東省自然科學基金面上項目：智能吸入遞藥經“除膜四步曲+細菌外膜擾動+抗毒力”策略抗銅綠假單胞菌所緻慢性肺部感染（課題負責人，No. 2024A1515011193，2024～2026年）

[9] 廣東省自然科學基金面上項目：針對幽門螺杆菌（膜）持續感染全過程的多功能遞藥系統的構建及其多維度清除機制研究（課題負責人，No. 2021A1515012621，2021～2023年）

[10] 廣東省自然科學基金面上項目：針對銅綠假單胞菌菌膜所緻頑固性肺部感染的全過程智能遞藥系統的構建及其阻斷細菌耐藥發生的機制研究（課題負責人，No. 2019A1515011954，2019～2021年）

[11] 中山大學交叉學科培育項目：靶向H. pylori biofilm提高幽門螺杆菌清除率的多功能脂質聚合物納米粒的研究（課題負責人，No. 18ykzd08，2018～2019年）

代表性論著

[1] M Xu#, SH Yu#, *, PY Li, YL Chen, YJ Chen, JY Pan, X Deng*, HY Hu*. Tailored multilayer nanoparticles against resistant P. aeruginosa by disrupting the thickened mucus, dense biofilm and hyperinflammation. J Control Release. 2025, 378:588-604.

[2] YL Wang#, Y Chen#, HJ Zhang, SH Yu, G  Yuan*, HY Hu*, Colon-targeted self-assembled nanoparticles loaded with berberine double salt ameliorate ulcerative colitis by improving intestinal mucosal barrier and gut microbiota. Colloid Surface B.2025, 245:114353.

[3] XF Zhang, JB Hao, TL Lu, YT Dong, YY Sun, YJ Yu, SX Li, SH Yu, HY Hu*,  Resveratrol-Loaded Versatile Nanovesicle for Alopecia Therapy via Comprehensive Strategies. Int J Nanomedicine. 2024, 19:13875-13900.

[4] JK Zhao#, SQ Hao#, Y Chen, XX Ye, PC Fang*, HY Hu*, Tauroursodeoxycholic acid liposome alleviates DSS-induced ulcerative colitis through restoring intestinal barrier and gut microbiota. Colloid Surface B. 2024, 236:113798.

[5] SH Yu, JY Pan, M. Xu, YJ Chen, PY Li*, HY Hu*, Antibacterial activity and mechanism of colistin-loaded polymeric nanoparticles for combating multidrug-resistant Pseudomonas aeruginosa biofilms: A synergistic approach. Int J Biol Macromol. 2024, 282(Pt 1):136757.

[6] YY Sun, TL Lu, JY Pan, HN He, M Xu, YY Chen, Y Chen, PC Fang, XX Ye, SX Li, HY Hu*, SH Yu*, Dual tobramycin and docosahexaenoic acid loaded nanoemulsions combating Pseudomonas aeruginosa-induced pulmonary infection. Colloid Surface B. 2024, 242:114088.

[7] SX Li, YH Huang, YY Sun, TL Lu, YT Dong, SH Yu, XF Zhang*, HY Hu*, Panax notoginseng saponins loaded W/O microemulsion for alopecia therapy with panthenol as cosurfactant to reduce skin irritation. Int J Pharmaceut. 2024, 663:124585.

[8] PY Li, JY Pan, YT Dong, YY Sun, YL Wang, K Liao, YL Chen, X Deng, SH Yu*, HY Hu*, Microenvironment responsive charge-switchable nanoparticles act on biofilm eradication and virulence inhibition for chronic lung infection treatment. J Control Release. 2024, 365: 219-235.

[9] XF Zhang, JK Zhao, SQ Hao, Q Ding, SH Yu, I.S. Mohammad, J Wang, HY Hu*, Biological activities and detoxification mechanisms of Clerodendrum chinense var. simplex, Marsdenia tenacissima and Arundina graminifolia: The Dai antidotes. Zhongshan Daxue Xuebao/Acta Scientiarum Natralium Universitatis Sunyatseni. 2023, 262: 89-99.

[10] MT Xiong#, YY Li#, HN He, SQ Hao, PC Fang, M Xu, Y Chen, YJ Chen, SH Yu*, HY Hu*, Cyclosporine A-loaded colon-targeted oral nanomicelles self-assembly by galactosylated carboxymethyl chitosan for efficient ulcerative colitis therapy. Eur J Pharm Biopharm. 2023, 189: 152-164.

[11] HH Rong#, YT Dong#, JK Zhao, XF Zhang, SX Li, YY Sun, TL Lu, SH Yu*, HY Hu*, Fetal milieu-simulating hyaluronic acid-dopamine-chondroitin sulfate hydrogel promoting angiogenesis and hair regeneration for wound healing. Int J Biol Macromol. 2023, 248:125739.

[12] YQ Zou#, XN Chen#, YY Sun, PY Li, M Xu, PC Fang, SQ Zhang, G Yuan, X Deng, HY Hu*, Antibiotics-free nanoparticles eradicate Helicobacter pylori biofilms and intracellular bacteria. J Control Release. 2022, 348: 370-385.

[13] XF Zhang, SX Li, YT Dong, HH Rong, JK Zhao, HY Hu*, A multifunctional cholesterol-free liposomal platform based on protopanaxadiol for alopecia therapy. Nano Res. 2022, 15: 9498-9510.

[14] X Yang, YL Wang, JK Zhao, HH Rong, YJ Chen, MT Xiong, XX Ye, SH Yu*, HY Hu*, Coordinated regulation of BACH1 and mitochondrial metabolism through tumor-targeted self-assembled nanoparticles for effective triple negative breast cancer combination therapy. Acta Pharm Sin B. 2022, 12: 3934-3951.

[15] YQ Rao#, YY Sun#, PY Li, M Xu, XN Chen, YL Wang, Y Chen, X Deng, SH Yu*, HY Hu*, Hypoxia-sensitive adjuvant loaded liposomes enhance the antimicrobial activity of azithromycin via phospholipase-triggered releasing for Pseudomonas aeruginosa biofilms eradication. Int J Pharmaceut.  2022, 623:121910.

[16] XN Chen, YQ Zou, SQ Zhang, PC Fang, SX Li, PY Li, YY Sun, G Yuan, HY Hu*, Multi-functional vesicles improve Helicobacter pylori eradication by a comprehensive strategy based on complex pathological microenvironment. Acta Pharm Sin B. 2022, 12: 3498-3512.

[17] Y Zhang, MT Xiong, XM Ni, JR Wang, HH Rong, YQ Su, SH Yu, I.S. Mohammad, S.S.Y. Leung, HY Hu*, Virus-Mimicking Mesoporous Silica Nanoparticles with an Electrically Neutral and Hydrophilic Surface to Improve the Oral Absorption of Insulin by Breaking through Dual Barriers of the Mucus Layer and the Intestinal Epithelium. ACS Appl. Mater. Interfaces. 2021, 13: 18077-18088.

[18] CC Lin, X Yang, HT Li, YQ Zou, I.S. Mohammad, HH Rong, YQ Rao, J Song, S.S.Y. Leung, HY Hu*, Self-assembled nanomedicine combining a berberine derivative and doxorubicin for enhanced antitumor and antimetastatic efficacy: Via mitochondrial pathways. Nanoscale. 2021, 13: 6605-6623.

[19] YN Shen, YQ Zou, XN Chen, PY Li, YQ Rao, X Yang, YY Sun, HY Hu*, Antibacterial self-assembled nanodrugs composed of berberine derivatives and rhamnolipids against Helicobacter pylori. J Control Release. 2020, 328: 575-586.

[20] YN Shen, PY Li, XN Chen, YQ Zou, HT Li, G Yuan, HY Hu*, Activity of Sodium Lauryl Sulfate, Rhamnolipids, and N-Acetylcysteine against Biofilms of Five Common Pathogens. Microb Drug Resist. 2020, 26: 290-299.

[21] XM Ni, Q Guo, YQ Zou, Y Xuan, I.S. Mohammad, Q Ding, HY Hu*, Preparation and characterization of bear bile-loaded pH sensitive in-situ gel eye drops for ocular drug delivery. Iran J Basic Med Sci. 2020, 23: 922-929.

[22] YL Wang#, HZ Huang#, HJ Zou, XY Tian, J Hu, PX Qiu, HY Hu*, GM Yan, Liposome Encapsulation of Oncolytic Virus M1 to Reduce Immunogenicity and Immune Clearance in Vivo. Mol. Pharmaceutics. 2019, 16: 779-785.

[23] J Song, CC Lin, X Yang, YQ Xie, P Hu, HT Li, WB Zhu, HY Hu*, Mitochondrial targeting nanodrugs self-assembled from 9-O-octadecyl substituted berberine derivative for cancer treatment by inducing mitochondrial apoptosis pathways. J Control Release. 2019, 294: 27-42.

[24] XW Li, MX Huang, KK Lo, WL Chen, YY He, YL Xu, HZ Zheng, HY Hu*, J Wang*, Anti-diabetic effect of a shihunine-rich extract of dendrobium loddigesii on 3t3-l1 cells and db/db mice by up-regulating AMPK–GLUT4–PPARα. Molecules. 2019, 24(14):2673.

[25] PY Li, XN Chen, YN Shen, HT Li, YQ Zou, G Yuan, P Hu, HY Hu*, Mucus penetration enhanced lipid polymer nanoparticles improve the eradication rate of Helicobacter pylori biofilm. J Control Release. 2019, 300: 52-63.

[26] XN Chen, PY Li, YN Shen, YQ Zou, G Yuan, HY Hu*, Rhamnolipid-involved antibiotics combinations improve the eradication of Helicobacter pylori biofilm in vitro: A comparison with conventional triple therapy. Microb Pathogenesis. 2019, 131: 112-119.

[27] XW Li, HP Chen, YY He, WL Chen, JW Chen, L Gao, HY Hu*, J  Wang*, Effects of rich-polyphenols extract of dendrobium loddigesii on anti-diabetic, anti-inflammatory, antioxidant, and gut microbiota modulation in db/db Mice. Molecules. 2018, 23(12):3245.

[28] HP Chen, XW Li, YL Xu, KK Lo, HZ Zheng, HY Hu*, J Wang*, YC Lin*, Study on the polar extracts of dendrobium nobile, D. officinale, D. loddigesii, and flickingeria fimbriata: Metabolite identification, content evaluation, and bioactivity assay. Molecules. 2018, 23(5):1185.

[29] HB Zhou, JS Chen, SY Li, JP Zhang, CE Zhu, H Ran, MH Luo, X Pan*, HY Hu*, CB Wu, Preparation of Acid-Resistant Microcapsules with Shell-Matrix Structure to Enhance Stability of Streptococcus Thermophilus IFFI 6038. J Food Sci. 2017, 82: 1978-1984.

[30] Q Xing, J Song, XH You, DL Xu, KX Wang, JQ Song, Q Guo, PY Li, CB Wu, HY Hu*, Microemulsions containing long-chain oil ethyl oleate improve the oral bioavailability of piroxicam by increasing drug solubility and lymphatic transportation simultaneously. Int J Pharmaceut. 2016, 511: 709-718.

[31] YQ Wang, LP Tang, W Yin, JS Chen, TD Leng, XK Zheng, WB Zhu, HP Zhang, PX Qiu, XX Yang, GM Yan, HY Hu*, Simultaneous determination of seven neuroactive steroids associated with depression in rat plasma and brain by high performance liquid chromatography-tandem mass spectrometry. Anal Sci. 2016, 32: 981-988.

[32] J Tuo#, YQ Xie#, J Song, YZ Chen, Q Guo, X Liu, XM Ni, DL Xu, HZ Huang, S Yin, WB Zhu, J Wu, HY Hu*, Development of a novel berberine-mediated mitochondria-targeting nano-platform for drug-resistant cancer therapy. J Mater Chem B. 2016, 4: 6856-6864.

[33] PY Li, J Song, XM Ni, Q Guo, H Wen, QY Zhou, YN Shen, YJ Huang, PX Qiu, SZ Lin, HY Hu*, Comparison in toxicity and solubilizing capacity of hydroxypropyl-β-cyclodextrin with different degree of substitution. Int J Pharmaceut. 2016, 513: 347-356.

[34] Q Guo#, J Cai#, PY Li, DL Xu, XM Ni, H Wen, D Liu, SZ Lin, HY Hu*, Comparison of bile salt/phosphatidylcholine mixed micelles in solubilization to sterols and stability. Drug Des Dev Ther. 2016, 10: 3789-3798.

[35] YL Wang, H Jiang, HZ Huang, YQ Xie, YS Zhao, XH You, LP Tang, YQ Wang, W Yin, PX Qiu, GM Yan, HY Hu*, Determination of neuroprotective oxysterols in Calculus bovis, human gallstones, and traditional Chinese medicine preparations by liquid chromatography with mass spectrometry. J Sep Sci. 2015, 38:  796-803.

[36] LP Tang, YQ Wang, TD Leng, HH Sun, YH Zhou, WB Zhu, PX Qiu, JX Zhang, BZ Lu, M Yan, WL Chen, XW Su, W Yin, YJ Huang, HY Hu*, GM Yan*, Cholesterol metabolite cholestane-3β,5α,6β-triol suppresses epileptic seizures by negative modulation of voltage-gated sodium channels. Steroids. 2015, 98: 166-172.

[37] SN Fu#, YQ Xie#, J Tuo, YL Wang, WB Zhu, SH Wu, GM Yan, HY Hu*, Discovery of mitochondria-targeting berberine derivatives as the inhibitors of proliferation, invasion and migration against rat C6 and human U87 glioma cells. MedChemComm. 2015, 6: 164-173.

[38] YZ Chen#, J Tuo#, HZ Huang, D Liu, XH You, JL Mai, JQ Song, YQ Xie, CB Wu, HY Hu*, Optimized mixed oils remarkably reduce the amount of surfactants in microemulsions without affecting oral bioavailability of ibuprofen by simultaneously enlarging microemulsion areas and enhancing drug solubility. Int J Pharmaceut. 2015, 487: 17-24.

[39] J Cai#, HZ Huang#, WJ Song, HY Hu*, JS Chen, LY Zhang, PY Li, R Wu, CB Wu, Preparation and evaluation of lipid polymer nanoparticles for eradicating H. pylori biofilm and impairing antibacterial resistance in vitro. Int J Pharmaceut. 2015, 495: 728-737.

[40] XH You, Q Xing, J Tuo, WJ Song, Y Zeng, HY Hu*, Optimizing surfactant content to improve oral bioavailability of ibuprofen in microemulsions: Just enough or more than enough?. Int J Pharmaceut. 2014, 471: 276-284.

[41] WJ Song, YL Wang, LY Zhang, SN Fu, Y Zeng, HY Hu*, Preparation and evaluation of polysaccharide sulfates for inhibiting Helicobacter pylori adhesion. Carbohyd Polym. 2014, 103: 398-404.

[42] YQ Ou, XK Zheng, YX Gao, MF Shu, TD Leng, Y Li, W Yin, WB Zhu, YJ Huang, YX Zhou, JJ Tang, PX Qiu, GM Yan, J Hu*, HZ Ruan*, HY Hu*, Activation of cyclic AMP/PKA pathway inhibits bladder cancer cell invasion by targeting MAP4-dependent microtubule dynamics. Urol Oncol-Semin Ori. 2014, 32: 47.e21-47.e28.

[43] Y Li, JQ Song, N Tian, J Cai, MH Huang, Q Xing, YL Wang, CB Wu, HY Hu*, Improving oral bioavailability of metformin hydrochloride using water-in-oil microemulsions and analysis of phase behavior after dilution. Int J Pharmaceut. 2014, 473: 316-325.

[44] L Li, J Tuo, YQ Xie, MH Huang, M Huang, RB Pi, HY Hu*, Preparation, transportation mechanisms and brain-targeting evaluation in vivo of a chemical delivery system exploiting the blood-cerebrospinal fluid barrier. J Drug Target. 2014, 22: 724-731.

[45] HY Hu#, YH Zhou#, TD Leng#, AL Liu, YQ Wang, XH You, JK Chen, LP Tang, WL Chen, PX Qiu, W Yin, YJ Huang, JX Zhang, LW Wang, HF Sang, GM Yan, The major cholesterol metabolite cholestane-3β,5α,6β-triol functions as an endogenous neuroprotectant. J Neurosci. 2014, 34: 11426-11438.

[46] SJ Zheng#, YQ Xie#, Y Li, L Li, N Tian, WB Zhu, GM Yan, CB Wu*, HY Hu*, Development of high drug-loading nanomicelles targeting steroids to the brain. Int J Nanomed. 2013, 9: 55-66.

[47] HY Hu, Y Huang, J Liu, XL Xu, T Gong, D Xiang, ZR Zhang, Medium-chain triglycerides based oil-in-water microemulsions for intravenous administration: Formulation, characterization and in vitro hemolytic activities. J Drug Deliv Sci Tec. 2008, 18: 101-107.

發明專利

[1] 胡海燕，張雪飛，李姝璇，董雅婷. 一種防脫生發的脂質體及其制備方法與應用.中國發明專利，專利号ZL202210577332.0，授權日期2024.04.02

[2] 胡海燕，鄒祎晴，陳小楠，王亞龍，李彭宇，饒義琴，孫瑩瑩. 雙胍衍生物及其應用與制劑.中國發明專利，專利号ZL202110414905.3，授權日期2023.03.28

[3] 胡海燕，陳小楠，鄒祎晴，李彭宇，饒義琴. 一種用于治療由幽門螺杆菌引起的疾病的囊泡.中國發明專利，專利号ZL202010644981.9，授權日期2023.01.13

[4] 胡海燕，申元娜，鄒祎晴，李彭宇，陳小楠，饒義琴. 基于小檗堿衍生物及鼠李糖脂的抗菌納米粒.中國發明專利，專利号ZL201910436175.X，授權日期2022.05.27

[5] 胡海燕，郭琴，楊絢，倪小敏，丁青，章溢，申元娜，林楚楚. pH敏感型熊膽眼用即型凝膠.中國發明專利，專利号ZL201710380150.3，授權日期2021.08.10

[6] 王軍，林永成，胡海燕，陳慧萍. 一種環草石斛提取物及其抗糖尿病用途.中國發明專利，專利号ZL201710013103.5，授權日期2021.03.10

[7] 胡海燕，庹珏，王亞龍，謝彥奇，付勝楠，顔光美，銀巍. 小檗堿衍生物及其用途. 中國發明專利，專利号ZL201310218566.7，授權日期 2016.8.10

[8] 胡海燕，付勝楠, 庹珏，謝彥奇，張國光，王亞龍，朱文博. 小檗堿衍生物的醫藥用途. 中國發明專利，專利号ZL201310218544.0，授權日期 2016.8.31

[9] 胡海燕，宋玮娟，付勝楠，曾穎. 聚半乳糖醛酸硫酸酯在制備抗幽門螺旋杆菌藥物中的應用. 中國發明專利，專利号ZL201110437407.7，授權日期 2014.10.1

[10] 胡海燕，蔡婕，王亞龍，王亞娜，林穗珍，石海濤. 5α-雄甾-3β,5,6β-三醇注射劑及其制備方法.中國發明專利，專利号ZL 2013 1 0206207.X，授權日期2015.3.26

[11] 顔光美，胡海燕，冷田東，桑韓飛，張靜夏，邱鵬新，周樹佳，陳婕思，遊秀華. 5α-雄甾(烷)-3β,5,6β-三醇在制備神經元保護藥物中的應用。 中國（專利号ZL201010224173.3，授權日期2011.8.24）, 美國（專利号8,809,309，授權日期2014.8.19）新加坡（專利号201208868-8，授權日期2014.2.14），加拿大（專利号2,802,133，授權日期2014. 1.14），澳大利亞（專利号2,011,276,800，授權日期2014.3.8），日本（專利号5681931，授權日期2015.1.23），韓國（專利号10‐1463477，授權日期2014.11.13），俄羅斯（專利号2541093，授權日期2014.12.24）

[12] 顔光美，胡海燕，張靜夏，邱鵬新，李玲，田甯. 一種5α-雄甾(烷)-3β,5,6β-三醇注射劑及其制備方法。 中國(專利号ZL201010292234.X，授權日期2012.11.21), 澳大利亞（專利号2011304917，授權日期2015.2.5），日本（專利号5750680，授權日期2015.5.29），韓國（專利号10-1468153，授權日期2014.11.25），俄羅斯（專利号2532354，授權日期2014.9.5）。

[13] 顔光美，胡海燕，孫環環，桑韓飛，冷田東，劉愛伶，銀巍，黃奕俊，張靜夏，邱鵬新。膽甾烷-3β,5α,6β-三醇在制備神經元保護藥物中的應用. 中國發明專利，專利号ZL200810198703.4，授權日期 2012.7.4.